Open-label, multicenter, phase III extension study of idalopirdine as adjunctive to donepezil for the treatment of mild-moderate alzheimer’s disease
This open-label extension study evaluated the long-term safety and tolerability of idalopirdine 60 mg/day as adjunctive therapy in patients with mild-moderate Alzheimer’s disease (AD). This extension study was a continuation of Studies 1 and 2 of the
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
08 January 2019
|
| In: |
Journal of Alzheimer's disease
Year: 2019, Jahrgang: 67, Heft: 1, Pages: 303-313 |
| ISSN: | 1875-8908 |
| DOI: | 10.3233/JAD-180595 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.3233/JAD-180595 Verlag: https://content.iospress.com/articles/journal-of-alzheimers-disease/jad180595 
|
| Verfasserangaben: | Lutz Frölich, Alireza Atri, Clive Ballard, Pierre N. Tariot, José Luis Molinuevo, Neli Boneva, Marie A. Geist, Lars L. Raket, Jeffrey L. Cummings |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1680868101 | ||
| 003 | DE-627 | ||
| 005 | 20230427033326.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191104s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3233/JAD-180595 |2 doi | |
| 035 | |a (DE-627)1680868101 | ||
| 035 | |a (DE-599)KXP1680868101 | ||
| 035 | |a (OCoLC)1341249781 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Frölich, Lutz |d 1956- |e VerfasserIn |0 (DE-588)1028327099 |0 (DE-627)730567516 |0 (DE-576)375813160 |4 aut | |
| 245 | 1 | 0 | |a Open-label, multicenter, phase III extension study of idalopirdine as adjunctive to donepezil for the treatment of mild-moderate alzheimer’s disease |c Lutz Frölich, Alireza Atri, Clive Ballard, Pierre N. Tariot, José Luis Molinuevo, Neli Boneva, Marie A. Geist, Lars L. Raket, Jeffrey L. Cummings |
| 264 | 1 | |c 08 January 2019 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 19.11.2019 | ||
| 520 | |a This open-label extension study evaluated the long-term safety and tolerability of idalopirdine 60 mg/day as adjunctive therapy in patients with mild-moderate Alzheimer’s disease (AD). This extension study was a continuation of Studies 1 and 2 of the | ||
| 773 | 0 | 8 | |i Enthalten in |t Journal of Alzheimer's disease |d London : Sage, 1998 |g 67(2019), 1, Seite 303-313 |w (DE-627)341909882 |w (DE-600)2070772-1 |w (DE-576)273884395 |x 1875-8908 |7 nnas |a Open-label, multicenter, phase III extension study of idalopirdine as adjunctive to donepezil for the treatment of mild-moderate alzheimer’s disease |
| 773 | 1 | 8 | |g volume:67 |g year:2019 |g number:1 |g pages:303-313 |g extent:11 |a Open-label, multicenter, phase III extension study of idalopirdine as adjunctive to donepezil for the treatment of mild-moderate alzheimer’s disease |
| 856 | 4 | 0 | |u https://doi.org/10.3233/JAD-180595 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://content.iospress.com/articles/journal-of-alzheimers-disease/jad180595 |x Verlag |
| 951 | |a AR | ||
| 992 | |a 20191104 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 1028327099 |a Frölich, Lutz |m 1028327099:Frölich, Lutz |d 60000 |e 60000PF1028327099 |k 0/60000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1680868101 |e 3536529224 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"11 S."}],"relHost":[{"title":[{"title":"Journal of Alzheimer's disease","subtitle":"JAD","title_sort":"Journal of Alzheimer's disease"}],"pubHistory":["1.1998/99 -"],"titleAlt":[{"title":"JAD"}],"part":{"volume":"67","text":"67(2019), 1, Seite 303-313","extent":"11","year":"2019","pages":"303-313","issue":"1"},"disp":"Open-label, multicenter, phase III extension study of idalopirdine as adjunctive to donepezil for the treatment of mild-moderate alzheimer’s diseaseJournal of Alzheimer's disease","note":["Gesehen am 07.03.2025"],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"recId":"341909882","origin":[{"dateIssuedDisp":"2025-","dateIssuedKey":"2025","publisher":"Sage ; IOS Press","publisherPlace":"London ; Amsterdam"}],"id":{"issn":["1875-8908"],"zdb":["2070772-1"],"eki":["341909882"]},"name":{"displayForm":["published in association with IOS Press"]}}],"name":{"displayForm":["Lutz Frölich, Alireza Atri, Clive Ballard, Pierre N. Tariot, José Luis Molinuevo, Neli Boneva, Marie A. Geist, Lars L. Raket, Jeffrey L. Cummings"]},"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"08 January 2019"}],"id":{"doi":["10.3233/JAD-180595"],"eki":["1680868101"]},"note":["Gesehen am 19.11.2019"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"recId":"1680868101","person":[{"given":"Lutz","family":"Frölich","role":"aut","display":"Frölich, Lutz","roleDisplay":"VerfasserIn"}],"title":[{"title_sort":"Open-label, multicenter, phase III extension study of idalopirdine as adjunctive to donepezil for the treatment of mild-moderate alzheimer’s disease","title":"Open-label, multicenter, phase III extension study of idalopirdine as adjunctive to donepezil for the treatment of mild-moderate alzheimer’s disease"}]} | ||
| SRT | |a FROELICHLUOPENLABELM0820 | ||